(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) said Wednesday that the U.S. Food and Drug Administration has accepted for review the EYLEA (aflibercept) Injection supplemental Biologics License ...

If approved, extended regimen would provide a longer treatment interval and additional dosing flexibility, alongside approved every 4- and 8-week dosing regimens TARRYTOWN, N.Y., June 29, 2022 ...